Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Philipp S. Lange is active.

Publication


Featured researches published by Philipp S. Lange.


EJNMMI research | 2013

Pulmonary vein isolation in patients with paroxysmal atrial fibrillation is associated with regional cardiac sympathetic denervation

Christian Wenning; Philipp S. Lange; Christoph Schülke; Alexis Vrachimis; Gerold Mönnig; Otmar Schober; Lars Eckardt; Michael Schäfers

BackgroundCircumferential pulmonary vein isolation (PVI) is the cornerstone of the current state-of-the-art management of atrial fibrillation (AF). However, the precise mechanisms behind AF relapses post PVI are still unknown. Since the activity of the autonomous nervous system is crucial in triggering paroxysmal AF, we hypothesized that PVI is associated with changes of cardiac sympathetic activity.MethodsSixteen patients with paroxysmal AF underwent cardiac iodine-123-meta-iodobenzylguanidine (123I-mIBG) planar cardiac imaging and single-photon emission computed tomography with low-dose computed tomography (SPECT/CT) for attenuation correction before and 4 weeks after PVI. The heart-to-mediastinum ratio (H/M ratio), washout rate (WR), regional myocardial uptake, and regional washout were analyzed.ResultsThe late H/M ratio was unchanged by PVI (pre, 2.9 ± 0.5 vs. post, 2.7 ± 0.6, p = 0.53). Four of the 16 patients (25%) displayed regional deficits before PVI. After PVI, regional deficits were present in ten patients (62.5%) with newly emerging deficits localized in the inferolateral wall. In a 6-month follow-up, four out of the ten patients (40%) with regional 123I-mIBG defects suffered from a recurrence of AF, while only one of the six patients (16.7%) without a regional 123I-mIBG defect experienced a recurrence.ConclusionA significant number of patients with paroxysmal AF show regional cardiac sympathetic innervation deficits at baseline. In addition, PVI is associated with newly emerging defects. The presence of regional sympathetic denervation after PVI may correlate with the risk of AF relapses.


Europace | 2016

Data on procedural handling and complications of pulmonary vein isolation using the pulmonary vein ablation catheter GOLD

Patrick Leitz; F. Güner; Kristina Wasmer; Philip Foraita; Christian Pott; Dirk G. Dechering; Stephan Zellerhoff; Simon Kochhäuser; Philipp S. Lange; Lars Eckardt; Gerold Mönnig

AIMS The second-generation multi-electrode-phased radiofrequency pulmonary vein ablation catheter (PVAC GOLD(®)) was redesigned with the intent to improve its safety and efficacy. METHODS AND RESULTS Using a prospectively designed single-centre database, we retrospectively analysed 128 consecutive patients (102 paroxysmal and 43 female) who underwent their first pulmonary vein isolation with the PVAC GOLD(®). The analysis focused on procedural data as well as in-hospital complications. Baseline characteristics of the patient collective were as follows: mean age 57.9 years, mean CHA2DS2-VASC was 1.73 ± 1.30; structural heart disease was present in seven patients. The PVAC GOLD(®) exhibited procedure durations of 123.1 min ± 27.9, duration of energy delivery was 18.3 min ± 11.4, and fluoroscopy duration was 16.0 min ± 7.7. The redesigned catheter shows major complication [major bleeding, transitory ischaemic attack (TIA), and pericardial tamponade] rates of 2.3% (n = 3). The overall rate of adverse events was 5.4% (n = 7). Bleeding complications were observed in three patients (2.3%), in particular there were two cases (1.6%) of minor bleeding and one case (0.8%) of major bleeding. Two patients suffered pericardial effusion, but there was no need for pericardiocentesis. Besides one TIA, there was no other thrombo-embolic event. Furthermore, one case of post-procedural fever was observed. No deaths, stroke, or haemorrhagic shock occurred. Of the 510 pulmonary veins, 508 could be reached with the PVAC GOLD(®) device using a non-steerable long sheath. CONCLUSION The PVAC GOLD(®) seems to have an acceptable safety profile. The handling is comparable with the previous generation PVAC(®).


Europace | 2016

Incidence and management of inadvertent puncture and sheath placement in the aorta during attempted transseptal puncture

Kristina Wasmer; Stephan Zellerhoff; Julia Köbe; Gerold Mönnig; Christian Pott; Dirk G. Dechering; Philipp S. Lange; Gerrit Frommeyer; Lars Eckardt

Aims Transseptal punctures (TSP) are routinely performed in cardiac interventions requiring access to the left heart. While pericardial effusion/tamponade are well-recognized complications, few data exist on accidental puncture of the aorta and its management and outcome. We therefore analysed our single centre database for this complication. Methods and results We assessed frequency and outcome of inadvertent aortic puncture during TSP in consecutive patients undergoing ablation procedures between January 2005 and December 2014. During the 10-year period, two inadvertent aortic punctures occurred among 2936 consecutive patients undergoing 4305 TSP (0.07% of patients, 0.05% of TSP) and in one Mustard patient during attempted baffle puncture. The first two patients required left ventricular access for catheter ablation of ventricular tachycardia. In both cases, an 11.5F steerable sheath (inner diameter 8.5F) was accidentally placed in the ascending aorta just above the aortic valve. In the presence of surgical standby, the sheaths were pulled back with a wire left in the aorta. Under careful haemodynamic and echocardiographic observation, this wire was also pulled back 30 min later. None of the patients required a closing device or open heart surgery. None of the patients suffered complications from the accidental aortic puncture and sheath placement. Conclusion Inadvertent aortic puncture and sheath placement are rare complications in patients undergoing TSP for interventional procedures. Leaving a guidewire in place during the observation period may allow introduction of sheaths or other tools in order to control haemodynamic deterioration.


Heart Rhythm | 2016

Lower rate of left atrial tachycardia after pulmonary vein isolation with PVAC versus irrigated-tip circumferential antral ablation

Kristina Wasmer; David Krüsemann; Patrick Leitz; F. Güner; Christian Pott; Stephan Zellerhoff; Dirk G. Dechering; Julia Köbe; Philipp S. Lange; Lars Eckardt; Gerold Mönnig

BACKGROUND Left atrial tachycardias (LAT) occur in about 5% of patients after irrigated-tip circumferential antral (CA) pulmonary vein isolation (PVI). They may cause debilitating symptoms in the patient and may be very difficult to treat. OBJECTIVE To assess the incidence of LAT after PVI with the multielectrode phased-radiofrequency pulmonary vein ablation catheter (PVAC) compared to circumferential antral PVI with an irrigated-tip catheter. METHODS We analyzed data from our ablation database. A total of 150 patients who underwent their first PVI with the PVAC system and 300 patients who underwent their first PVI with irrigated-tip circumferential antral (CA) radiofrequency ablation were matched by age and sex, as well as by type of atrial fibrillation. RESULTS Of 150 PVAC patients, only 1 patient (0.7%) developed LAT during mean follow-up of 21 ± 14 months. The mechanism was macroreentry and the patient underwent successful ablation at our institution. Eleven of 300 irrigated-tip CA PVI patients (3.7%) developed LAT during mean follow-up of 22 ± 14 months and subsequently underwent ablation (P = .05). CONCLUSION LAT occurs more frequently after irrigated-tip CA PVI compared to single-shot-device ablation with PVAC. Apart from being less technically demanding, lower incidence of LAT may influence choice of ablation technology.


Clinical and Experimental Pharmacology and Physiology | 2017

Antiarrhythmic properties of ivabradine in an experimental model of Short‐ QT ‐ Syndrome

Gerrit Frommeyer; Christian Ellermann; Sven Kaese; Simon Kochhäuser; Philipp S. Lange; Dirk G. Dechering; Lars Eckardt

The If channel inhibitor ivabradine is recommended for treatment of chronic heart failure. However, ivabradine also inhibits human ether‐a‐go‐go (hERG) mediated potassium currents. The aim of the present study was to assess the electrophysiologic effects of ivabradine in an experimental model of short‐QT‐syndrome. Twelve rabbit hearts were isolated and Langendorff‐perfused. After obtaining baseline data, pinacidil, an IK‐ATP channel opener, was infused (1 μmol/L). Eight endo‐ and epicardial monophasic action potentials and a 12‐lead ECG showed a significant abbreviation of QT interval (−32 ms, P<.05) and shortening of action potential duration at 90% of repolarization (APD90; −22 ms, P<.05). The shortening of ventricular repolarization was accompanied by a reduction of effective refractory period (ERP; −20 ms, P<.05). Thereafter, hearts were additionally treated with ivabradine (5 μmol/L) leading to an increase of QT interval (+31 ms, P<.05), APD90 (+15 ms, P<.05) as well as of ERP (+38 ms, P<.05) and post‐repolarization refractoriness (PRR, +33 ms, P<.05) as compared with sole pinacidil infusion. Under baseline conditions, ventricular fibrillation (VF) was inducible by a standardized pacing protocol including programmed stimulation and burst stimulation in 3 of 12 hearts (6 episodes). After application of 1 μmol/L pinacidil, 6 of 12 hearts were inducible (22 episodes). Additional infusion of 5 μmol/L ivabradine led to a significant suppression of VF. Only two episodes could be induced in 1 of 12 hearts. In the present study ivabradine reversed the electrophysiologic effects of pharmacologically simulated short‐QT syndrome. Ivabradine demonstrated antiarrhythmic properties based on an increase of both ERP and PRR.


European Journal of Pharmacology | 2016

Divergent electrophysiologic profile of fluconazole and voriconazole in an experimental whole-heart model of proarrhythmia.

Gerrit Frommeyer; Christina Fischer; Philipp S. Lange; Patrick Leitz; Michael Fehr; Harilaos Bogossian; Peter Milberg; Lars Eckardt

In several case reports a prolongation of the QT-interval and even proarrhythmic effects of fluconazole and voriconazole were reported. The aim of the present study was to investigate if application of fluconazole or voriconazole has the potential to provoke polymorphic ventricular tachycardia in a sensitive model of proarrhythmia. In female rabbits, fluconazole (10, 30 and 50 µM, n=6) and voriconazole (10, 30 and 50 µM, n=6) were infused after obtaining baseline data. Eight endocardial and epicardial monophasic action potentials and a simultaneously recorded 12-lead ECG showed a significant QT prolongation after application of fluconazole as compared with baseline (10 µM:+12 ms, 30 µM:+22 ms, 50 µM:+37 ms; P<0.05) accompanied by an increase of action potential duration (APD90). Administration of voriconazole also induced QT prolongation (30 µM:+10 ms, 50 µM:+20 ms, P<0.05). Spatial dispersion of repolarization remained stable in voriconazole-treated hearts while fluconazole induced a significant increase (30 µM:+15 ms, 50 µM:+16 ms; P<0.05). Lowering of potassium concentration in bradycardic AV-blocked hearts did not provoke any early afterdepolarizations (EADs) or polymorphic ventricular tachycardia in voriconazole-treated hearts. Application of fluconazole led to the reproducible induction of EADs in 4 of 6 hearts and polymorphic ventricular tachycardia in 3 of 6 hearts (36 episodes). In the present study, voriconazole demonstrated a safe electrophysiologic profile despite significant QT prolongation. In contrast, fluconazole led to a more marked prolongation of myocardial repolarization combined with a more marked increase of dispersion of repolarization. These results imply that application of fluconazole might be torsadogenic and the QT-interval should be closely monitored.


Europace | 2016

Safety profile of multielectrode-phased radiofrequency pulmonary vein ablation catheter and irrigated radiofrequency catheter

Kristina Wasmer; P. Foraita; Patrick Leitz; F. Güner; Christian Pott; Philipp S. Lange; Lars Eckardt; Gerold Mönnig


Cardiovascular Toxicology | 2017

Severe Proarrhythmic Potential of the Antiemetic Agents Ondansetron and Domperidone

Gerrit Frommeyer; Christina Fischer; Christian Ellermann; Philipp S. Lange; Dirk G. Dechering; Simon Kochhäuser; Michael Fehr; Lars Eckardt


Cardiovascular Toxicology | 2018

Additive Proarrhythmic Effect of Combined Treatment with QT-Prolonging Agents

Gerrit Frommeyer; Christina Fischer; Christian Ellermann; Dirk G. Dechering; Simon Kochhäuser; Philipp S. Lange; Kristina Wasmer; Michael Fehr; Lars Eckardt


Journal of Interventional Cardiac Electrophysiology | 2018

Comparing learning curves of two established “single-shot” devices for ablation of atrial fibrillation

Patrick Leitz; Gerold Mönnig; F. Güner; Dirk G. Dechering; Kristina Wasmer; Florian Reinke; Philipp S. Lange; Lars Eckardt; Gerrit Frommeyer

Collaboration


Dive into the Philipp S. Lange's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

F. Güner

University of Münster

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge